Wow. A nice lineup for Symposium 3. Chaired by Dr. Winblad, Presentation 2 by Dr. Zetterberg and Presentation 4 by Dr. Cummings. All three of those are members of the Resverlogix Neurodegenerative Clinical and Science Advisory Board. Plus, Presentation 3 is by Resverlogix's Dr. Kulikowski.  

Thursday Dec 5th 4.00 p.m

SYMPOSIUM 3: Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies

Chairman: Bengt Winblad, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden

PRESENTER 1: Dementias, who and how to treat and by what specialty . Addressing problem and current and potential future therapeutic practices

Charles DeCarli, MD, FAAN, FAHA, UC Davis, CA, USA

PRESENTER 2: Fluid biomarkers that predict and project brain health

Henrik Zetterberg, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

PRESENTER 3: The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease

Ewelina Kulikowski, SVP Research and Development, Resverlogix Corporation, Calgary, Canada

PRESENTER 4: Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease

Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA